Biomarkers in Parkinsonian Syndromes

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Apr 10, 2014

Keywords

ClinConnect Summary

This clinical trial is focused on studying specific biological markers in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP). These conditions affect the nervous system and involve abnormal protein build-up, which can make diagnosis and treatment challenging. The main goal of the trial is to compare levels of a protein called oligomeric alpha-synuclein in the cerebrospinal fluid (the fluid around the brain and spinal cord) of patients with these disorders. Researchers hope that discovering these markers will help improve diagnosis and lead to better treatment options in the future.

To participate in the trial, patients need to be diagnosed with PD, MSA, or PSP and be between the ages of 30 and 74. They must also provide written consent and be covered by the national health system. Participants will need to attend two study visits where they will undergo blood tests and a procedure to collect cerebrospinal fluid. The study will help researchers understand how these markers relate to the severity and progression of the diseases. It's important to note that patients on certain blood-thinning medications or with specific blood abnormalities will not be included in the study.

Gender

ALL

Eligibility criteria

• • Patients receiving anticoagulants, showing abnormal coagulation on blood testing or thrombocytopenia are excluded from this study.
• • Patients showing more than 500 erythrocytes per mm3 of LCR are excluded from this study.
• • PD patients
• * inclusion criteria:
• • Patients suffering from PD according to clinical criteria (Hughes et al, 1992)
• • Written informed consent
• • Patient covered by the national health system
• * exclusion criteria:
• • Patient under tutelage
• • patient covered by the national health system
• • MSA patients
• * inclusion criteria:
• • Patients suffering from "possible" or "probable" MSA according to clinical consensus criteria (Gilman et al, 2008), age \> 30
• • Written informed consent
• • Patient covered by the national health system
• * exclusion criteria:
• • UMSARS IV score \>4 points
• • Patient under tutelage
• • PSP patients
• * inclusion criteria:
• • Patients suffering from PSP according to NNIPPS trial criteria (Bensimon et al., 2009), age \> 40
• • Written informed consent
• • Patient covered by the national health system
• * exclusion criteria:
• • PSPRS item 26 score \>3 points
• • Patient under tutelage